Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial

Inclusion Criteria: * Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II/III) * Clinical stage III\~IVb(UICC 7th) * Meet at least one factor below :1 primary tumor SUVmax\>10 in 18F-FDG PET/CT;2 primary tumor volume\>30cm3;3 mutiple metastatic cervical lymph node with at least one's short diameter\>4cm; 4 T4N2M0; 5 T1-4N3M0;6 EBV-DNA\>2×10E4 copy/l * Range from 18～70 years old * WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L * ALT or AST \< 2.5×ULN、bilirubin \< 1.5×ULN * OSerum creatinine \< 1.5×ULN Exclusion Criteria: * Central nervous system metastases * Suitable for local treatment * Uncontrolled seizure disorder or other serious neurologic disease * Clinically significant cardiac or respiratory disease * Drug or alcohol addition * Do not have full capacity for civil acts * Severe complication, active infection * Concurrent immunotherapy or hormone therapy for other diseases * Pregnancy or lactation